The MMRF Blog - Multiple Myeloma Research Foundation

The MMRF Blog

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.

Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BG, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P. J Clin Oncol. 2015 Sep 10;33(26):2863-9. doi: 10.1200/JCO.2015.61.2267. Epub 2015 Aug 3. PMID: 26240224 [PubMed - in process] READ MORE

Posted: September 24, 2015

A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.

Benson DM Jr, Cohen AD, Jagannath S, Munshi NC, Spitzer G, Hofmeister CC, Efebera YA, Andre P, Zerbib R, Caligiuri MA. Clin Cancer Res. 2015 Sep 15;21(18):4055-61. doi: 10.1158/1078-0432.CCR-15-0304. Epub 2015 May 21. PMID: 25999435 [PubMed - in process] READ MORE

Posted: September 24, 2015

Optimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2A

Sarkar S, van Gelder M, Noort W, Xu Y, Rouschop KM, Groen R, Schouten HC, Tilanus MG, Germeraad WT, Martens AC, Bos GM, Wieten L. Cancer Immunol Immunother. 2015 Aug;64(8):951-63. doi: 10.1007/s00262-015-1694-4. Epub 2015 Apr 29. PMID: 25920521 [PubMed - in process] READ MORE

Posted: August 20, 2015

Page 48 of 87« First...102030...4647484950...607080...Last »